Tech Transfer eNews Blog
Industry-Sponsored Research Management

U of Copenhagen spinoff developing Antibody Drug Conjugate cancer therpeutics


By Jesse Schwartz
Published: November 8th, 2017

The University of Copenhagen and the Capital Region of Denmark have partnered with biotech company ADCendo ApS to accelerate the development of novel, targeted cancer treatments for certain bone, connective tissue and brain cancers.

The agreement is centered around innovations by researchers at the Finsen Laboratory that target the novel uPARAP receptor using an Antibody Drug Conjugate (ADC) therapeutic. This kind of drug links an antibody to a biologically active drug or cytotoxic compound, allowing the ADC drug to combine the targeting capabilities of an antibody with the cell-killing properties of cytotoxic drugs.

“By targeting antigens that are highly expressed in certain cancer tissues and that hold strong ability of being internalized into the cancer cell, we can actively aim for and attack the cancer,” says Henrik Stage, CEO of ADCendo.

“We will now take the most promising ADC drug candidate and take it through preclinical and clinical development and hope it may end up as a new treatment option with the potential to significantly impact the lives of cancer patients,” Stage adds.

Under the terms of the license agreement with ADCendo, the University of Copenhagen and the Capital Region of Denmark are eligible to receive milestone payments if certain development and registration goal are reached, in addition to royalty payments.

“A promising spinout biotech company is always a significant achievement,” says Niels Skjærbæk, senior executive advisor at the University of Copenhagen, who helped facilitate the deal. “The ADCendo founders have been very focused and displayed great determination through this process. We are therefore all very excited about this new cancer biotech company, and we will follow the drug development challenges with great interest.”

Source: Markets Insider

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment